In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Insight Molecular Diagnostics, with a price target of $8.00. The company’s shares closed last Friday at $3.35.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Flaten is a 4-star analyst with an average return of 11.9% and a 54.03% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Harrow Health, Insight Molecular Diagnostics, and MDxHealth.
Currently, the analyst consensus on Insight Molecular Diagnostics is a Moderate Buy with an average price target of $6.13.
Based on Insight Molecular Diagnostics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $518 thousand and a GAAP net loss of $9.74 million. In comparison, last year the company earned a revenue of $104 thousand and had a GAAP net loss of $4.53 million
Read More on IMDX:
Disclaimer & DisclosureReport an Issue
- Insight Molecular says kidney transplant patient achieved ‘immune reset’
- Insight Molecular Diagnostics Extends Executive Employment Agreement
- Insight Molecular Diagnostics announces attendance at two industry conferences
- Insight Molecular Diagnostics Approves Executive Salary Increases
- Insight Molecular Diagnostics announces novel registry database
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
